Kura Oncology, Inc. (KURA) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$10.21

From 52W high−40.84%

Volume3.99M

Market cap$715.24M

P/E (TTM)—

P/S (TTM)9.3x

Div yield—

Key dataNov 4, 2026

Open

$10.21

From 52W high

−40.84%

Volume

3.99M

Market cap

$715.24M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.7x

P/E (TTM)

—

RSI (14)

31.4

MomentumView details →

1D Return

−18.62%

YTD Return

−18.77%

SummaryUpdated Jun 1, 2026

Kura Oncology, Inc. (NASDAQ:KURA) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in San Diego, California. The company went public in September 2015 and focuses on developing precision medicines for cancer treatment. Kura has built a pipeline of small molecule drug candidates designed to target specific genetic mutations and pathways involved in various cancers, with its lead programs showing particular promise in blood cancers like acute myeloid leukemia (AML) and solid tumors including gastrointestinal stromal tumors (GIST).

Ask drillr about Kura Oncology, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.7x

EV/Sales

2.9x

P/S (TTM)

9.3x

P/B (TTM)

14.8x

ProfitabilityView details →

Gross Margin

94.73%

Net Margin

−384.30%

EBITDA Margin

−381.19%

ROE (TTM)

−612.78%

ROA (TTM)

−50.49%

Asset Turnover

0.12x

GrowthView details →

Revenue YoY

−7.27%

EPS YoY

−49.12%

FCF YoY

—

Revenue CAGR 3Y

+25.24%

EPS CAGR 3Y

−57.43%

EBITDA YoY

−52.35%

MomentumView details →

1D Return

−18.62%

YTD Return

−18.77%

1Y Return

−15.09%

RSI (14)

31.4

vs 50D SMA

−22.97%

vs 200D SMA

−14.02%

Capital & dividendView details →

Debt/Equity

0.50x

Current Ratio

4.73x

Quick Ratio

4.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.77

EPS Surprise

12.23%

Beats (12Q)

8/12

Next Q EPS Est

−$0.82

Avg Surprise (4Q)

−156.52%

Rev Surprise

3.53%

Financials snapshotView financials →

Revenue (TTM)

77.22M

Net Income (TTM)

−296.77M

Op. CF (TTM)

−111.76M

Next earningsNov 10, 2026 →

Latest newsMore news →

Kura Oncology, Inc. shares fell 18.5% after JOHNSON & JOHNSON released data related to a blood cancer therapy.25m ago

Kura Oncology, Inc. announced that it will report its third-quarter 2026 financial results after market close on November 10, 2026.1d ago

Similar companies

Sagimet Biosciences Inc.SGMT Wave Life Sciences Ltd.WVE Achieve Life Sciences, Inc.ACHV Solid Biosciences Inc.SLDB CANbridge Pharmaceuticals Inc.01228.HK Brii Biosciences Limited02137.HK Find similar companies →

Latest newsMore news →

Kura Oncology, Inc. shares fell 18.5% after JOHNSON & JOHNSON released data related to a blood cancer therapy.25m ago Kura Oncology, Inc. announced that it will report its third-quarter 2026 financial results after market close on November 10, 2026.1d ago